| Rating | Target Price Range | Current Price (Close 2026-11-11) | Margin of Safety | Time Horizon |
|---|---|---|---|---|
| Neutral | RMB 720–990 (base-case fair value, midpoint RMB 849) | RMB 840.00 | approx. −14% (vs. lower bound of base-case fair value) | 12 months |
Total shares outstanding: 151.95 million, corresponding to a market cap of approx. RMB 127.6 billion. All valuation, scenario, and odds analyses in this report are anchored to the 2026-11-11 closing price of RMB 840; market data from other dates are separately time-stamped.
Lianxun Instruments is a scarce Chinese test equipment company riding the spillover chain of AI compute infrastructure buildout. According to the company's own disclosures in its prospectus, it is the world's second vendor to launch the full suite of core test instruments for 1.6T optical modules, tied to the capacity expansion cycles of leading optical module makers such as Innolight and Eoptolink. In the first three quarters of 2026, revenue reached RMB 4.044 billion (+401.9%), net profit attributable to shareholders RMB 2.006 billion (+1975.6%), and blended gross margin 75.04% — the inflection in earnings has been confirmed by three consecutive quarterly reports. However, the current price of RMB 840 already largely prices in this report's base case (2027E net profit of RMB 3.9–4.7 billion × 28–32x exit multiple, fair value range RMB 720–990, midpoint RMB 849): back-solving from a neutral 30x exit multiple, the current price requires only approx. RMB 4.25 billion of 2027 net profit (+38%) — demand volume is not over-discounted. The true vulnerability lies in margins: the 49.6% net margin for the first three quarters is 2–3x the highest level among global instrument peers, and the dual pressure of tax normalization and fading 1.6T scarcity premium has not been priced into sell-side consensus (2027E approx. RMB 5.99 billion, implying a 50%+ net margin). Combined with the lockup expiry of approx. 15.98% of share capital around April 2027 (approx. RMB 20.4 billion at current prices, lower-bound estimate) and the already-launched H-share offering, the 12-month odds are nearly symmetric (vs. current price: base +1%, bull +49%, bear −52%). This report assigns a Neutral rating: excellent quality, but fully priced. We recommend awaiting three validation points — the 2026-11-20 earnings briefing, the 2027-01 earnings pre-announcement, and cloud providers' 2027 capex guidance — and reassessing allocation only after a margin of safety emerges below the lower bound of base-case fair value (approx. RMB 720).
Environment: Mid-stage of an upward AI capex cycle, overlaid with the high-volatility phase of a recently listed stock. Exogenously driven demand (cloud capex → optical module capacity expansion and generational transition → volume-and-price double hit for test equipment) is still being delivered, but the market has already priced in decelerating cloud capex growth for 2027 (consensus range approx. +22% to +50%); the debate is only over the magnitude of the slowdown. After retracing approx. 54% from its 52-week high of RMB 1,824.32, the stock is caught in a tug-of-war between "earnings delivery vs. valuation digestion" (a cumulative 37.55% decline over 20 trading days in late October; a single-day rebound of over 10% on November 11).
The three most important trends over the next 6–12 months:
Primary share price driver: The exogenous demand chain of AI capex → optical module maker expansion → test equipment orders (the first-order determinant of revenue growth direction), followed in order by net margin duration (the ability to sustain the 75% gross margin) and the supply shocks from lockup expiry/H-share issuance.
Verifiable expectation gap: This report's 2027E net profit midpoint of RMB 4.3 billion is approx. 28% below sell-side consensus of RMB 5.99 billion; the core disagreement is the net margin assumption (ours: 43–46% vs. Street's implied 50%+). Falsification/confirmation signals are clear: Q4 2026 quarterly gross margin (a break below 72% would signal the start of normalization), the effective tax rate in the 2026 annual tax settlement, and the mass-production timing of Keysight's and domestic competitors' 1.6T/3.2T equipment.
Validation catalysts and falsification conditions (see tracking section at the end): 2026-11-20 Q3 earnings briefing (chairman's first attendance), 2027-01 annual earnings pre-announcement (whether the lower bound is ≥ RMB 3.0 billion), 2027-01/02 2027 capex guidance from the four major North American cloud providers, sample submission and order conversion for 2.4T/3.2T equipment, and H-share filing documents (to verify fundraising rumors). Core falsification signals: contract liabilities declining QoQ for two consecutive quarters, quarterly gross margin below 72%, or aggregate cloud 2027 capex guidance growth below 30%.
Entry prerequisites (currently unmet): None of the three key variables — pace of demand deceleration, net margin duration, lockup expiry and H-share pricing — has been validated, and the current price approximates the probability-weighted fair value midpoint (approx. RMB 843, mid-range weighted), leaving no margin of safety. Until evidence turns favorable and the price falls significantly below the base-case lower bound (approx. RMB 720), this does not constitute an actionable opportunity.
Key evidence:
The industry-level attribution of the high growth is clear and backed by first-hand statements: per the Q3 report, "primarily benefiting from the development of AI technology, rising global compute demand, and accelerated data center construction... strong expansion intentions among optical module and optical chip makers have rapidly boosted demand for the company's communication test instruments and optoelectronic device test equipment." Two qualifications should be retained: first, the "world's second / duopoly" claim is a narrow self-reported scope from the prospectus (referring to the combination of the 65GHz sampling oscilloscope + 120GBaud clock recovery + 1.6Tbps BERT), with no independent third-party verification, and Anritsu has already released the MP2110A all-in-one instrument covering 10G–1.6T optical module manufacturing test (official product page), making the competitive scope for the "duopoly" claim even broader; second, the company's products are capital expenditures for downstream customers, and the company was still loss-making (net loss of RMB 55 million) in 2023 — the cyclical nature of this revenue round has yet to be falsified. Three quarters of validation confirm "the high growth is real," not "the growth is sustainable through 2028."
Key evidence:
This report's base case for 2027E is revenue of RMB 8.8–10.0 billion (+28% to +45%) and net profit of RMB 3.9–4.7 billion, approx. 28% below sell-side consensus of RMB 5.99 billion (n=20, as of 2026-11-12). Three reasons for the lower estimate: first, optical module shipment growth is not equal to test equipment revenue growth — equipment purchases are determined by optical module makers' capex, and in the late stage of an expansion cycle equipment orders peak before module shipments do; using industry shipment growth to underwrite an equipment vendor's full-year revenue involves a mismatch of scope; second, generational transitions may truncate the procurement window — 3.2T is expected to enter commercial validation in 2027–2028, with 2.4T demand emerging in early 2027 (per CITIC Securities/Kaiyuan Securities, as relayed by media); if the transition comes early, the 1.6T test equipment procurement peak could be front-loaded and then decline; third, contract liabilities of RMB 924 million represent only approx. 0.37x Q3 standalone revenue — prepaid coverage of less than one quarter — and the company has disclosed its order backlog only qualitatively, without amounts; "visibility extending into 2027" is therefore an inference. This thesis carries significantly more uncertainty than C1, hence the confidence of only 0.50; it should be upgraded if both the 2027-01 earnings pre-announcement and cloud capex guidance beat expectations.
Key evidence:
The certain and uncertain parts of net margin normalization must be separated: the certain part is the tax rate — normalization of 12.46% toward the 15% customary for high-tech enterprises will directly erode approx. 2–3 percentage points of net margin in 2027, with the income tax catch-up already concentrated in Q3; the uncertain part is the timing and magnitude of the gross margin decline — the 75.04% gross margin includes a 1.6T scarcity premium, which will be compressed by a counterattack from Keysight (leader of the foreign camp with approx. 84% China market share in 2024) and Anritsu, and by entries from domestic players like RIGOL; but there is no public evidence yet on competitors' mass-production timing for the full 1.6T suite: if competitors scale only after H2 2027, net margin could hold above 48%, close to sell-side assumptions; if they enter within 2027, it would normalize toward 43–46% or lower. This report treats 43–46% as the base-case assumption (gross margin 75%→68–70%, tax rate 15%), with sensitivity disclosures in the valuation section; sell-side consensus implies a 50%+ net margin persisting — this is the core point of disagreement between this report and the market. Additionally, credit plus asset impairments totaled RMB 124 million in the first three quarters (vs. RMB 21 million a year earlier), or 5.4% of total profit; as receivables (RMB 1.898 billion) and inventory (RMB 1.779 billion) scale up, this is also a marginal drag on margins.
Key evidence:
Two-way test of the market's implied expectations: volume side not over-discounted — back-solving from a neutral 30x exit multiple, the current price requires only approx. RMB 4.25 billion of 2027 net profit (+38% vs. Huatai's 2026E) and approx. RMB 9.7 billion of revenue (+40%), below LightCounting's industry forecast of +76% and the delivery trajectory of the previous AI optical module cycle leader (Innolight's 2024 revenue +122.6%); margin side stretched — the implied net margin assumption of approx. 44% requires the 2026 historical extreme of 49.6% to be largely sustained, whereas mature global instrument companies' net margins run only 15.8% (Keysight) to 26.9% (Siglent). The probability-weighted value of the three scenarios (bear RMB 400 / base RMB 849 / bull RMB 1,253, probabilities 25%/50%/25%) is approx. RMB 843 ≈ the current price of RMB 840 — the market is essentially pricing in "base-case delivery": neither a margin of safety nor an obvious bubble. It must be emphasized that this equilibrium conclusion is sensitive to the exit multiple assumption: if in 2027 the market begins pricing in the digestion of 2028 AI capex and the exit multiple compresses to 22x, the base-case net profit of RMB 4.3 billion would correspond to approx. RMB 623 per share (−26% vs. current price) — this is the main downside vulnerability of this thesis.
Key evidence:
Two scopes must be strictly distinguished: the lockup expiry is a deterministic date event — around 2027-04-24 (one year post-listing), the above four institutions' 15.98% stake becomes tradable, and this is only a lower-bound estimate; the prospectus's pre-issuance shareholder register also lists pre-IPO holders such as Jiaqiao Fukai, Hengyitai, Haitong Innovation, Yongxin Rongyao, and Accotest; the exact total of unlocked shares is subject to the lock-up commitment details in the listing announcement and the circulating-share announcements at that time. Given the currently tiny free float (only 14,044 shareholders as of the Q3 report), a potential supply on the order of tens of billions of RMB represents the single largest valuation headwind for H1 2027 against a 41x 2026E P/E. The H-share offering is a launched but significantly uncertain potential dilution — if the rumored USD 1 billion (approx. RMB 7.15 billion) raise is assumed with an issuance price at a 15%–30% discount to the A-share price (RMB 630–588), it implies approx. 6.9%–7.4% new share capital; neither the rumored amount nor the banking lineup has been confirmed by the company and does not constitute a certain input. A positive counterweight also exists: on 2026-11-05 the actual controller proposed a RMB 100–150 million buyback (more signal than size, only approx. 0.12% of market cap), and with RMB 3.75 billion in cash-like assets and zero leverage, the company faces no financing urgency — launching the H-share at a high valuation is closer to a strategic move for global branding and an offshore financing channel, but the market will simultaneously read it as industrial capital's verdict on the valuation range.
| Metric | FY2023 | FY2024 | FY2025 | 2026Q1-3 (latest period) |
|---|---|---|---|---|
| Operating revenue (RMB 100mn) | 2.76 | 7.89 | 11.94 | 40.44 |
| Revenue YoY | +28.6% | +185.9% | +51.4% | +401.9% |
| Net profit attributable to parent (RMB 100mn) | −0.55 | 1.40 | 1.74 | 20.06 |
| Adjusted net profit attributable to parent (RMB 100mn) | −0.63 | 1.32 | 1.70 | 19.34 |
| Overall gross margin | 60.50% | 63.63% | 58.84% | 75.04% |
| Net margin attributable to parent | −20.1% | 17.8% | 14.5% | 49.6% |
| Net operating cash flow (RMB 100mn) | −0.05 | 0.81 | 0.78 | 15.21 |
| Free cash flow (OCF−CapEx, RMB 100mn) | — | approx. −0.31 | — | 13.84 |
| Cash + trading financial assets (RMB 100mn) | — | — | 3.26 (beginning of year) | 37.50 (2026-09-30) |
| Interest-bearing debt (RMB 100mn) | — | — | — | 2.49 (2026-09-30) |
| Debt-to-asset ratio | — | — | — | 41.96% (2026-09-30) |
| Contract liabilities (RMB 100mn) | — | — | 1.61 (beginning of year) | 9.24 (+474.7%) |
| R&D expense (RMB 100mn) / expense ratio | — | — | — | 3.99 / 9.88% |
Note: The company only listed in April 2026; 2023–2024 audited figures are from the prospectus and 2025 audited figures from the listing announcement; 2023/2025 free cash flow is not shown due to incomplete full-year capital expenditure data; net debt/EBITDA is not applicable (net cash position of approx. RMB 3.5bn). Balance sheet stock items are all as of end-Q3 2026 (2026-09-30).
Reasons for metric changes (items with YoY change ≥ ±20%, all with company explanations):
Quarterly trajectory: 2026 revenue climbed steeply quarter by quarter — Q1 revenue RMB 488mn (+142.5%) → Q2 single-quarter RMB 1.043bn → Q3 single-quarter RMB 2.512bn (+711.4%, +140.8% QoQ); net profit attributable to parent Q1 RMB 119mn → Q2 RMB 448mn → Q3 RMB 1.439bn (+3,488%, +221% QoQ), with Q3 single-quarter net margin at 57.3% and single-quarter gross margin approx. 77.6% (estimated from cost data in the Q3 consolidated income statement).
Guidance delivery: On 2026-10-13 the company voluntarily guided net profit attributable to parent for the first three quarters at RMB 1.9–2.1bn; the actual figure of RMB 2.006bn landed near the midpoint, continuing its post-IPO record of "guidance delivered as stated" (Q1 guidance issued twice and the semi-annual report guidance were both delivered; see the management section).
Earnings quality: Operating cash flow for the first three quarters was RMB 1.521bn (vs. −RMB 25mn in the prior-year period), with Q3 at RMB 973mn; OCF/net profit attributable to parent was 0.76 — a marked improvement over 0.58 in 2024 and 0.45 in 2025, but the substance of the 57.3% single-quarter net margin warrants two caveats: first, the effective tax rate for the first three quarters was 12.46%, and normalization toward 15% in 2027 is a certain headwind; second, non-recurring items include approx. RMB 70mn of fair-value gains on wealth management products (from wealth management purchases with IPO proceeds; the RMB 72mn gap between adjusted and reported profit roughly corresponds to this).
Versus expectations: At the current price, PE is approx. 41.5x Huatai's 2026E net profit of RMB 3.079bn, implying a Q4 single-quarter net profit attributable to parent of approx. RMB 1.07bn, down approx. 25% QoQ from Q3 — given that Q4 has historically been a peak delivery season for the company (IPO inquiry noted a high Q4 revenue share), this implied sell-side assumption looks conservative; this report's 2026E net profit attributable to parent of RMB 3.05–3.50bn (Q4 single-quarter RMB 1.04–1.49bn, −5% to +4% QoQ) cross-validates it. Has the market priced it in: after the stock pulled back from its late-October high, the 11-11 close of RMB 840 implies approx. 38–42x 2026E — a stand-off between "earnings delivery and valuation digestion"; sell-side consensus is still being revised up sharply (consensus revised up approx. +298% over 90 days), with no stable "beat/miss" benchmark yet established.
Model in brief: An asset-light manufacturer of "instruments + equipment + solutions." Two product lines: electronic measurement instruments (sampling oscilloscopes, clock recovery units, bit error rate analyzers, precision source meters — highly standardized, high unit price and gross margin) and semiconductor test equipment (optical chip burn-in/sorting, silicon photonics wafer testing, SiC wafer-level burn-in, KGD sorting — with automation mechanisms, highly customized, gross margin approx. 35pp lower). Production is order-driven, revenue recognized upon delivery and acceptance; downstream is capital procurement by optical module/optical chip manufacturers, so revenue fluctuates with expansion cycles, and recurring revenue has a low share (test components and services approx. 6.25% of main business revenue, per the Jan–Sep 2025 basis). In Jan–Sep 2025 main business revenue, optical communications downstream accounted for 78.94% and SiC power devices for 19.04%. The revenue model is essentially "order-driven capital goods," and contract liabilities (RMB 924mn) are the most important leading order indicator — the core monitoring variable repeatedly emphasized in tracking this chapter.
Cash content of earnings: OCF/net profit attributable to parent was 0.58 in 2024, 0.45 in 2025, and 0.76 in the first three quarters of 2026 — the first two years were persistently below the 0.8 warning line (credit terms and inventory buildup tying up working capital), with substantial improvement in 2026 on higher advance receipts; FCF/net profit for the first three quarters was approx. 0.69. Net working capital consumed in the first three quarters of 2026 was approx. RMB 698mn ÷ revenue increase of RMB 3.238bn ≈ 0.22 — the expansion did not excessively consume cash. Recurring earnings test: Adjusted profit for the first three quarters was RMB 1.934bn vs. RMB 2.006bn reported, the RMB 72mn gap mainly reflecting fair-value gains on wealth management products; core earnings are essentially in line with book figures. Share-based payment expense is a recurring item (Sep-YTD 2022–2025: RMB 39.44/48.45/44.37/32.90mn respectively; in 2024 it was 31.6% of net profit attributable to parent due to a small profit base; 2026H1 RMB 22mn, approx. 3.8% of the period's attributable profit), fully expensed and highly transparent.
Return on capital: Annualized ROIC for the first three quarters of 2026 was approx. 38% (conservative basis, denominator includes idle IPO proceeds) — far above WACC (approx. 10%); return on invested capital is excellent, a "true growth" rather than pseudo-growth signal. Clearly asset-light: intangible assets plus goodwill together account for only approx. 0.6% of total assets.
CapEx quality: CapEx for the first three quarters was RMB 138mn (vs. RMB 112mn for full-year 2024), mainly directed at a new plant (5 IPO-funded projects totaling RMB 1.711bn, still in early stages); the CapEx/depreciation ratio is high but represents expansionary investment rather than a maintenance black hole; most of the net IPO proceeds of RMB 1.907bn have been temporarily placed in wealth management products (trading financial assets RMB 2.709bn); cash is ample. The maintenance-vs-growth split is not disclosed, so further determination is not possible.
Moat and quality red flags: The moat derives from generational technology scarcity (mass-production capability for the 1.6T trio, 113 granted invention patents, R&D staff at 40% of headcount, and leadership of national key R&D program projects), customer certification barriers at top-tier customers (Zhongji Innolight, Eoptolink, Accelink, Hisense, Huagong Zhenyuan, Lumentum, Coherent, etc.), and positioning in category expansion from moving testing upstream (silicon photonics wafers/KGD/burn-in). Three red flags: OCF/net profit persistently below 0.8 in 2024–2025; recurring share-based payment dilution; and planning an H-share refinancing just 6 months after listing (capital operations moving faster than dividend returns). Top-five customer concentration reached 52.81% in 2023 (down to 36.94% in Jan–Sep 2025); heavy customer concentration tightly coupled to downstream expansion cycles is an endogenous risk of the model.
Consistency of words and deeds: pragmatic, prefers conservative guidance, strong delivery track record. Three sets of "commitment vs. delivery": ① The prospectus registration draft (2026-04-20) guided 2026Q1 revenue at RMB 400–430mn and attributable profit at RMB 43–51mn; actual results were RMB 488mn and RMB 119mn, substantially above guidance ceilings (the listing announcement raised guidance to RMB 480–500mn and RMB 110–125mn three days later); ② The listing announcement's Q1 guidance: actual results landed within the range; ③ The 2026-10-13 guidance of attributable profit of RMB 1.9–2.1bn for the first three quarters: actual RMB 2.006bn landed within the range. Three for three, and initial guidance systematically conservative — from a buy-side perspective this is a positive signal (management does not overdraw expectations).
Shareholder friendliness: neutral, leaning financing-oriented. No cash dividends post-listing (2026 interim: 4.8 bonus shares per 10 shares, no cash dividend), no completed buybacks (the controlling shareholder just proposed a RMB 100–150mn buyback on 2026-11-05, pending board review); six months after an IPO raising RMB 2.102bn (net RMB 1.907bn), H-share planning has begun — potential second-round dilution. The controlling shareholder and concert parties (54.79% combined pre-IPO) are locked up for 36 months and committed not to reduce holdings if the stock trades below IPO price or net asset value, or if dividends fall short of targets. Verdict: tilted toward raising capital rather than returning it; the buyback proposal is the first signal of a shift but the magnitude is too small.
Risk signals: No equity pledges, no record of secondary-market selling by directors/supervisors/officers (share changes at end-September were all from bonus issuances); minimal related-party transactions (only a RMB 1.6mn contribution in May 2026 for a 17.78% stake in a joint venture); both first-instance patent lawsuits with Aehr were won, with appeals pending by both sides (see risk section); the core technical team comes from Keysight (Chairman Hu Haiyang and others have Keysight China experience), giving intimate knowledge of overseas leaders' tactics — and vice versa.
The company does not disclose a formal segment report; the table below uses the prospectus product-line basis (Jan–Sep 2025 main business revenue; 2026 quarterly reports do not disclose product-level data, so full-year trends must wait for the annual report — itself a limitation on tracking granularity):
| Product line | Revenue share | Gross margin (estimated) | Trend | Business logic in one sentence |
|---|---|---|---|---|
| Communications test instruments | 41.53% | approx. 76.7% | +152% in 2024, accelerating in 2026 with 1.6T ramp | High-end standardized instruments; the 1.6T trio is globally scarce; profit driver (approx. 53.6% of gross profit) |
| Optoelectronic device test equipment | 32.31% | approx. 38.2% | +268% in 2024; Jan–Sep 2025 already 173% of full-year 2024 | CoC burn-in/KGD sorting/silicon photonics wafer test systems with automation mechanisms; high volume, low margin |
| SiC power device test equipment | 19.04% | approx. 60.6% | +259% in 2024; Jan–Sep 2025 fell to 68% of full-year 2024 (decelerating) | Wafer-level burn-in + KGD sorting; automotive-driven; demand fluctuates |
| Electrical performance test (semiconductor) | 2.02% | approx. 58.6% | +119% in 2024 | WAT test systems/precision source meters; small scale; memory testing is an IPO-funded direction |
Profit driver and revenue driver diverge: Communications test instruments contribute approx. 53.6% of gross profit on 41.5% of revenue — the earnings core; optoelectronic device equipment contributes revenue volume but at only approx. 38% gross margin. A gross margin structure gap of nearly 39pp (76.7% vs. 38.2%) reflects two fundamentally different businesses: the former is standardized measurement instruments with high technical barriers (pricing power from chip + algorithm + software know-how), the latter customized production-line equipment containing mechanical automation (high hardware cost share, order-by-order negotiation). This structure makes overall gross margin highly sensitive to product mix — the jump in overall gross margin to 75.04% in 2026 is mainly due to rising share and unit prices of the high-margin communications test instruments; if 1.6T instrument growth slows in 2027 and equipment's share rebounds, overall gross margin faces passive downside pressure — consistent in direction with the active normalization pressure in C3.
Disclosure on insufficient periods: The company listed in April 2026; formal disclosure spans fewer than 3 periods (2023–2024 audited figures in the prospectus, 2025 audited figures in the listing announcement, and three quarterly reports in 2026); cross-period consistency can only be partially assessed.
Accounting red flags (by severity):
Cross-period consistency checks:
Overall judgment: Based on available disclosures, no obvious accounting tricks found (revenue recognition basis, related-party transactions, and goodwill are all clean); the main flaws are impairment elasticity scaling with size and insufficient quarterly disclosure granularity (no product, customer, or on-hand order value breakdown), leaving external trackers reliant on indirect indicators such as contract liabilities.
| Metric | Value | Notes |
|---|---|---|
| Share price / market cap | RMB 840.00 / RMB 127.6bn | Frozen anchor at the 2026-11-11 close |
| PE (TTM) | approx. 61.3x | TTM attributable profit RMB 2.083bn; listed only six months, historical percentile unavailable and statistically meaningless — in a high-growth breakout phase, PE percentile is reference only, not a headline cheap/expensive signal |
| PE (2026E) | 41.5x (Huatai, RMB 3.079bn) / 35.3x (Sinolink, RMB 3.619bn) | Two latest valid sell-side anchors |
| PE (2027E) | 21.3x (consensus RMB 5.99bn) / 29.7x (this report's base case RMB 4.3bn) | The core divergence lies in net margin assumptions |
| PB | approx. 26.4x | Book value per share RMB 31.82 (2026-09-30) |
| EV/Sales (TTM) | approx. 28.0x | EV = market cap − net cash of RMB 3.5bn |
Peer comparison (multiples as of the 2026-11-12 close):
| Company | Market cap | PE (TTM) | Revenue growth 2026 first three quarters | Gross/net margin | Core difference |
|---|---|---|---|---|---|
| Lianxun Instruments | RMB 127.6bn | 61.3x | +401.9% | 75.0% / 49.6% | Globally scarce 1.6T test instrument position; purest AI exposure |
| Keysight (KEYS) | approx. USD 38.5bn (FY2025 revenue USD 5.37bn) | approx. 20–25x forward at maturity (historical norm reference) | Latest quarter revenue +36.5% | Net margin 15.8% (FY25) | Global full-category leader; Lianxun's only same-tier 1.6T competitor; overwhelming scale and ecosystem |
| Rigol Technologies | RMB 7.6bn | 72.9x | +27.5% | Gross margin approx. 58% (sector average basis) | Domestic oscilloscope leader, entering optical communications testing (potential competitor) |
| Siglent Technologies | RMB 10bn | 54.1x | +32.9% | Net margin 26.9% | Premiumization of general-purpose instruments; diversified downstream, best domestic earnings quality |
| Kunchi Usoft | RMB 2.9bn | 86.4x | −7.4% | Gross margin 62.6% | Wireless RF simulation; no overlap with optical communications; sector valuation-band reference only |
Back-solving from a neutral 30x exit multiple, the current RMB 127.6bn market cap requires approx. RMB 4.25bn of 2027 attributable profit (+38% vs. Huatai's 2026E) and approx. RMB 9.7bn of revenue (+40%). Against industry-chain demand math: LightCounting's +76% Ethernet optical module growth in 2027, TrendForce's USD 84.1bn pluggable optical module revenue in 2027 (+76%, 1.6T at 56% share), and Zhongji Innolight's precedent of +109.8% volume growth in 2026H1 — the implied volume growth (+40%) is below industry levels and is supportable; the company can deliver as long as it merely holds share. The real stretch is on the margin side: the implied ~44% net margin requires roughly sustaining the highest profit margin in the history of the instruments industry for two years. In one sentence: the current price requires the company to achieve "steady volume growth without margin decline," while reality points to high certainty on volume but a fairly certain direction of margin normalization — offsetting each other, pricing is fair but full.
Note: the 83% growth-option share is not a mechanical indicator of "overvaluation" — this stock has hit a structural demand inflection point (AI capex → generational switching → step-change in testing intensity; see the quantitative chain in E7), and the growth-quality gate has been passed (ROIC of ~38% far exceeds WACC of 10%, asset-light, genuine cash flows, three quarters of delivered results); the market is paying for a ramp path that has been partially validated. EPV is a downside floor (~RMB 146/share), not a final verdict; whether the price is expensive is decided by the scenario distribution.
| Scenario | Probability | Fair Value Range (RMB) | Central Value | Key Assumptions | vs. Current Price |
|---|---|---|---|---|---|
| Bear | 25% | 320–480 | 400 | 2027 cloud capex growth <20%, optical module capacity expansion winding down; revenue only +10–15%, net margin 33–35%; exit at 20–26x (lower end of Keysight's mature-period multiple plus sector downside band) | −52% |
| Base | 50% | 720–990 | 849 | 1.6T becomes the main driver + 800G stays high + SiC steady growth; revenue RMB 8.8–10.0 billion (+28–45%, implying market share no longer rising but defended), net margin 43–46%, net profit attributable RMB 3.9–4.7 billion; exit at 28–32x | +1% |
| Bull | 25% | 1,027–1,500 | 1,253 | CPO testing front-loading ramp-up + 2.4T/3.2T samples converting to orders + global share gains + successful H-share listing; revenue RMB 11.0–12.5 billion (+60–80% ≈ industry growth rate), net margin sustained at 46–48%, net profit attributable RMB 5.2–6.0 billion (≈ consensus); exit at 32–38x | +49% |
Probability-weighted central value of ~RMB 843 (weighted by range midpoints) ≈ current price of RMB 840. Basis for anchoring the base-case exit multiple at 28–32x: PEG ≈ 1.0 (against ~30% net profit CAGR for 2026–2028E); Keysight's mature-period 20–25x serves as the lower-bound reference (Lianxun's growth rate is 3–4x theirs); the A-share instruments sector at 54–86x provides the upper-bound backdrop (but peers' profit scale is an order of magnitude smaller, so not directly comparable). Do not anchor on its own current 61x — using the current-price multiple to justify the current price is circular reasoning. Sensitivity: if the exit multiple compresses to 22x (2028 AI capex digestion priced in early), base-case net profit of RMB 4.3 billion corresponds to ~RMB 623 (−26%); the ramp calculation (2027E net profit attributable of RMB 4.3 billion × 30x = RMB 129 billion market cap ≈ RMB 849/share) is consistent with the base range in the scenario table. External anchor comparison: the most bullish sell-side estimate, Huatai at RMB 1,414 (implying ~36x on consensus 2027E), falls within the bull range; there are no sell-side sell ratings or bearish target prices whatsoever (external bear anchors are systematically absent); Huatai itself cut from RMB 3,171.75 to RMB 1,414 within six weeks, and sell-side forecast variance is enormous — neither end of that range constitutes a boundary constraint for this report's scenarios.
| Period | Revenue | Net Profit Attributable to Parent | Core Assumption Drivers |
|---|---|---|---|
| FY2026E | RMB 6.7–7.2 billion | RMB 3.05–3.50 billion (ex-non-recurring: RMB 2.95–3.35 billion) | Q4 single-quarter revenue +5.5%–25% QoQ (peak-season deliveries); Q4 net margin 40–48% (partial tax-rate normalization, excluding fair-value wealth-management gains) |
| FY2027E | RMB 8.8–10.0 billion | RMB 3.9–4.7 billion | 1.6T volume ramp + 800G staying high + SiC/overseas steady growth; net margin 43–46% (15% tax rate annualized for the full year, gross margin reverting to 68–70%); ~28% below consensus of RMB 5.99 billion |
Methodology note: the company provides no formal earnings guidance (only the qualitative statement that "the order backlog is relatively ample"); the table above is a synthesis of actual Q3 report figures + third-party industry forecasts + net-margin regression assumptions. The greatest uncertainty lies in order-recognition cadence (extreme single-quarter QoQ volatility) and the net-margin path (each ±2pp of net margin impacts 2027E by ~±RMB 200 million and base-case fair value by ~±RMB 40).
Verdict: Fairly Priced — quality and price scored separately. Quality: a globally scarce 1.6T test-instrument positioning, 75% gross margin, 38% ROIC, RMB 1.52 billion of operating cash flow, RMB 3.55 billion of net cash with zero leverage — a scarce, high-quality growth stock on the STAR Market. Price: the current RMB 840 ≈ base-case fair central value of RMB 849; margin of safety approximately −14% (on the base-case fair-value lower bound of RMB 720); zero-growth value covers only 17%; the odds across the three scenarios are nearly symmetric (+49%/+1%/−52%), and with the 2027 share unlock and H-share supply ahead and the net-margin reversion not yet realized, the upside scenario is harder to realize than the downside scenario is to trigger. Low-liquidity risk does not apply (single-day turnover of RMB 4.275 billion on 11-11, 16.75% turnover rate — extremely liquid; but the turnover rate itself indicates intense chip-game dynamics and noisy price discovery).
The market segments in which the company truly competes are optical-communication test instruments (the communications-test track within electronic measurement instruments) and semiconductor optoelectronic/power device test equipment. Market-size figures (Frost & Sullivan, cited in Lianxun's prospectus, 2025-08 edition):
| Segment | 2024 | 2029E | CAGR |
|---|---|---|---|
| Global optical-communication test instruments | USD 950 million | USD 2.02 billion | ~16.3% |
| China optical-communication test instruments | RMB 3.30 billion | RMB 6.59 billion | ~14.8% |
| Global electronic measurement instruments (broader category) | USD 12.93 billion | USD 18.38 billion | ~7.3% |
| Global semiconductor optoelectronic device test equipment | USD 780 million | USD 1.31 billion | ~11% |
| China SiC power-device test equipment | RMB 740 million | RMB 3.35 billion | ~35.3% |
Static forecasts have seriously lagged reality: F&S's figures above were formed in mid-2025 and do not reflect 2026 AI-driven volume — LightCounting (2026-10) has raised 2026 Ethernet optical module growth to approximately +120% and 2027 to approximately +76%; the company's total revenue for the first three quarters of 2026 was RMB 4.044 billion, already roughly 1.2x the size of F&S's entire 2024 China optical-communication test instrument market (RMB 3.30 billion, including semiconductor equipment and overseas revenue), indicating that "market explosion + domestic share leap" happened simultaneously.
Quantified chain of the demand inflection (drivers × unit consumption × penetration × share):
Upstream: IC chips (high-speed ADCs/FPGAs), PCBA, precision machined parts — bargaining power for high-end components rests with overseas chip vendors; upstream export controls are a common industry constraint, and the company's bargaining power vis-à-vis upstream is relatively weak. Midstream (where the company operates): integrated manufacturing of optics, mechanics, and electronics plus high-speed signal processing and software algorithms — the thickest-margin link; the company's 2026H1 gross margin of 70.79% is significantly above domestic instrument peers (47–63%) and downstream assembly manufacturing. Downstream: optical module/optical chip manufacturers (Zhongji Innolight, Eoptolink, Accelink, Hisense, HG TrueLight, Lumentum, Coherent, Broadcom, Sumitomo, etc.) and semiconductor manufacturers (BYD Semiconductor, Silan Microelectronics, SJ Semiconductor, San'an Optoelectronics, etc.); the ultimate payer is cloud providers' AI capex. The company's downstream bargaining position is relatively strong due to technology scarcity: very few alternative suppliers exist for high-end 1.6T test equipment, and customers must prepay (contract liabilities of RMB 924 million vs. RMB 161 million at the start of the year as evidence); but customer concentration is high (top five account for 36.9%–52.8%), and the single-customer bargaining power of large head customers cannot be ignored.
Demand is dual-driven by AI capex and generational switching (see above); supply shows structural tightness: test equipment is the bottleneck in optical module R&D and mass-production efficiency; head optical module manufacturers have strong expansion intent (per the Q3 report text), and the company schedules production by order with inventory +255% built up for delivery. Competitive landscape (Frost & Sullivan, 2024 China market): overseas vendors (Keysight, Anritsu, Tektronix, EXFO, etc.) combined ~84% vs. domestic ~16%; the company's 9.9% ranks third and is the only domestic player in the top five. Niche championship positions: No. 1 in China for optoelectronic device test equipment, No. 1 in China for SiC wafer-level burn-in systems with 43.6%, third in SiC KGD sorting with 12.1% (first among domestic players), while precision source-measure units remain dominated by Tektronix/NI/Keysight at 80%+ combined. Fourfold barriers to entry: core know-how in high-speed signal acquisition/clock recovery/bit-error analysis (113 granted invention patents); qualified-supplier certification by head customers plus mass-production scale requirements; funding thresholds from sustained high R&D investment; endorsement by national-level projects (national key R&D program major-instruments special project). Two genuine variables in the landscape: first, "only two companies worldwide in mass production of the full 1.6T three-instrument suite" is the prospectus's self-reported claim — Anritsu's MP2110A (integrated 10G–1.6T BERT + sampling oscilloscope) is already on the market, and Keysight is accelerating its AI-testing positioning (latest FY2026 quarter revenue +36.5%), so the contestable bandwidth is wider than the "duopoly" narrative suggests; second, domestic players such as RIGOL (2026H1 revenue +37%, explicitly attributed by brokers to optical communications) are encroaching on the company's home turf; over the next 2–3 years, the high-speed testing track will shift from "scarcity dividend" to comprehensive competition on "technology + delivery + price."
The industry is in the mid-upswing of the AI optical-interconnect supercycle: 800G in volume ramp, the first year of 1.6T, and a generational leap in testing intensity. But two authoritative voices have flagged deceleration: LightCounting (2026-03) warned that 2026 optical module capacity may exceed customer demand; Goldman Sachs (as relayed, 2026-06) noted market consensus of ~USD 920 billion in 2027 hyperscaler capex, with growth decelerating from ~84% in 2026 to ~22% (LightCounting in 2026-10 again raised 2027 cloud capex growth to ~50%) — the consensus divergence range is +22% to +50%; the divergence itself is the biggest industry risk signal. Leading indicators: North American cloud providers' quarterly capex guidance, optical module manufacturers' production/sales and capex (Zhongji Innolight 2026H1 output +100.6%), the company's contract liabilities QoQ, and the pace of LightCounting forecast revisions. As the leading segment of optical module makers' capex, test-equipment orders will peak before module shipments peak — this is a transmission-lag risk, and the reason C2 confidence is capped. Regulatory and policy backdrop is systematically favorable: the 2023 Politburo collective study called for "winning the battle for technological self-reliance in scientific instruments," the Action Plan for the Development of the Intelligent Inspection Equipment Industry, and the catalog of encouraged industries for structural adjustment; the company is a national-level specialized-and-new "little giant" and undertakes national key R&D program special projects. The only external variable: export controls on upstream high-speed IC chips, and rumored potential FCC restrictions on Chinese optical modules (Morgan Stanley views them as more likely to start from the 3.2T generation, with limited impact on current 800G/1.6T — rumor-level, not yet implemented).
See the E6 benchmarking table. Additional overseas reference: VIAVI (FY2025 revenue USD 1.084 billion, +8.4%, GAAP operating margin of only 5.3%) focuses on carrier network testing; datacenter high-speed module production testing is not its main battlefield. CETC SKY Test Instruments (unlisted; IPO registration approved 2026-06) is a central-SOE full-category platform with 2025 revenue of RMB 2.398 billion (+16.9%), gross margin 47.46%, and government subsidies accounting for 30.6% of total profit — first-tier in scale but with profitability quality and market orientation significantly below the company's. Essential difference between the company and peers: the three listed domestic instrument companies (RIGOL/Siglent/Kunheng) have diversified end markets, growth of 7%–37%, and net margins of 9%–27%; the company's end market is concentrated in the single AI optical-interconnect track, with growth and margins several times those of peers — elasticity and risk share the same source, which is precisely the root of the valuation dispute.
Global challenger + No. 1 domestic player in China: share trend clearly rising (9.9% and third place in 2024 → 2026 revenue already ~1.2x the size of the industry's total). Sources of moat: generational technology scarcity, positioning as one of the very few vendors covering the full module-chip-wafer chain, and first-mover advantage from head-customer certification and prepayment lock-in. Note on juxtaposed claims: the company describes itself as "the second company worldwide in a full suite of core 1.6T test instruments" (self-reported in the prospectus; the narrow definition is the three-instrument combination, whereas Anritsu has an integrated single-unit 1.6T product); third-party figures show "9.9% of China's optical-communication test instrument market, third place" (F&S, 2024) — the gap between the two claims is the definitional difference between "full-suite combination" and "single-product coverage"; investors should anchor industry standing on third-party share figures and understand product generational standing via the self-reported claim. Positioning risk: its nature as a chaser is unchanged — the overseas camp still holds 84% of share and iteration leadership; the company must complete "sample-validation-ramp" for every product generation within a 2-year window, and falling behind once triggers a re-rating.
Overall verdict: Neutral (12 months; judgment confidence 0.50). Lianxun Instruments is the Chinese test-equipment company with the highest fundamental delivery in this AI optical-interconnect cycle — technology positioning, profitability, cash-flow turnaround, and management's guidance-delivery record are all positive evidence; but the current price of RMB 840 has essentially priced in the base case (2027E net profit attributable of RMB 3.9–4.7 billion), the margin of safety is negative (~−14% on the base-case lower-bound basis), and none of the three overhang variables — net-margin reversion (tax normalization + premium decay), the magnitude of 2027 cloud capex deceleration, and the share unlock and H-share supply — has materialized. The mismatch between a great company and a great price is not rare among high-quality growth stocks — the discipline is to wait for one of them to be corrected: either the price falls to a point of safety margin, or evidence proves that net margin/demand duration exceed assumptions.
Strategy: no deployable opportunity at present. Monitoring/verification sequence: ① 2026-11-20 earnings briefing (Q4 order visibility, 2.4T/3.2T sample progress, buyback plan); ② 2027-01 annual results preview (whether net profit floor ≥ RMB 3.0 billion); ③ 2027-01/02 cloud providers' 2027 capex guidance (aggregate growth ≥30% as demand-side confirmation; <30% triggers bear-case re-rating); ④ 2027-04 annual report + share-unlock announcement (exact unlock list and scale, gross margin by product, final settled tax rate). Price discipline: below the base-case fair-value lower bound of ~RMB 720, provided the above evidence has not deteriorated, a margin of safety begins to appear; a break below the bear-range upper bound of RMB 480 would signal the market is pricing in capacity-expansion wind-down, requiring a wholesale re-examination of the thesis rather than bottom-fishing.
Risk and Catalyst Summary (written record):
(All financial data in this report sourced from: the company's prospectus registration draft (2026-04-20), listing announcement (2026-04-23), and 2026 Q1/interim/Q3 reports and contemporaneous announcements; industry data sourced from: Frost & Sullivan (cited in the prospectus), LightCounting, TrendForce (media-relayed basis noted as such); sell-side expectations sourced from: aggregated institutional earnings forecasts such as iFinD/THS (2026-11-12 basis).)